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Objectives. To determine the sedative and respiratory eﬀects of clonidine when used to evaluate growth hormone (GH) secretion
in children with Prader Willi Syndrome (PWS). Methods. The study prospectively evaluated children with PWS who received
clonidine (0.15mg/m2) to assess GH responsiveness. Patients were studied up to four times over three years. Vital signs, oxygen
saturation, and sedation level were recorded at baseline and every ﬁve minutes following clonidine. Changes between baseline
and post-clonidine were evaluated using a repeated measurement analysis. Results. Sixty studies were performed on 17 patients,
mean age 30.4 ± 15.0 months. The mean ± SD dose of clonidine was 0.074 ± 0.027mg (5.3 ± 1.72mcg/kg). All patients achieved
a sedation score of 4 to 5 (drowsy to asleep). Mean declines in respiratory rate (7.5 ± 6.1 breaths/min; P<. 001), and oxygen
saturation (2.2±2.0%; P<. 001) occurred following clonidine. Five patients (29%) experienced oxygen saturations ≤94% on nine
occasions. Three oxygen desaturations were accompanied by partial airway obstruction. Conclusions. Clonidine doses to assess
GH secretion often exceed doses used for sedation and result in signiﬁcant respiratory depression in some children with PWS.
There was no association between oxygen desaturation and BMI.
1.Introduction
Prader Willi Syndrome (PWS) is a complex genetic disorder
associated with abnormalities of respiratory control [1–6].
Respiratory dysfunction contributes to signiﬁcant morbidity
and early mortality in this population [7–9]. Pulmonary
problems include decreased respiratory muscle function
and a propensity for upper airway obstruction due to
pharyngeal hypotonia and narrowness [6, 8]. Abnormalities
in respiratory function are particularly common during
sleep and are characterized by impaired ventilatory and
arousal responses to hypoxia and hypercapnia in both
adult and pediatric patients with PWS [5]. Sleep dis-
ordered breathing is one of the minor diagnostic cri-
teria for PWS [10] and encompasses the entire spec-
trum of sleep-related disturbances from alveolar hypoven-
tilation and hypoxemia to obstructive sleep apnea [11–
13].
Clonidine is a central alpha2-adrenergic receptor agonist
used as a provocative agent to assess growth hormone (GH)
secretion but also has analgesic and sedative properties and
is used as a preanesthetic medication in adults and children
[14]. Unlike most sedatives clonidine has minimal clinically
signiﬁcant respiratory depressant eﬀects (decrease in oxygen
saturation of ≤1%) in healthy adults when used at oral doses
of 3 to 4μg/kg [15]. Similarly, in healthy children no oxygen
saturations <95% were observed at oral clonidine doses of
4μg/kg as a preanesthetic [16]. However, studies speciﬁcally
assessingrespiratorydrivedemonstratereductionsinminute
ventilation and carbon dioxide responsiveness in otherwise
healthy subjects following clonidine administration [15, 17].
The respiratory depressant eﬀects are more evident and even
life threatening when large doses of clonidine are given,
particularly in cases of clonidine overdose [17–21].
The aim of this study was to assess the respiratory and
sedative eﬀects of clonidine in children with PWS when used2 International Journal of Pediatric Endocrinology
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Figure 1: Study design schema.
as a provocative test for GH stimulation. We hypothesized
that PWS patients, a patient population with abnormalities
in respiratory drive and increased tendencies toward airway
obstruction, are at risk of developing clinical signs of
respiratory depression deﬁned as a reduction in oxygen
saturation ≤94% and/or airway obstruction following a
standard dose of clonidine to assess GH responsiveness.
2. Patientsand Methods
2.1. Study Design. The study was part of a randomized,
longitudinal investigation that evaluated changes in energy
expenditure and body composition before and following
growth hormone (GH) administration in young patients
withPWS[22,23].Aspartofthisstudyprotocol,assessments
of provoked endogenous GH secretion following clonidine
were performed up to four times during the three-year
period, yielding 60 studies in 17 subjects. The intra-assay
coeﬃcient variation is 4% per Nichols Institute Diagnostics,
San Juan Capistrano, CA. The University of Wisconsin (UW)
Health Sciences Center Institutional Review Board and the
UW General Clinical Research Center (GCRC) approved the
study. Informed written consent was obtained from parents
or a legal guardian prior to study enrollment.
2.2. Patient Population. Eligible subjects were children with
PWS: (1) conﬁrmed by high-resolution cytogenetics, ﬂuo-
rescent in situ hybridization and/or methylation studies, (2)
between the ages of 4 and 37 months at the time of inclusion,
and (3) na¨ ıve to GH therapy. All patients received a standard
dose of oral clonidine, 0.15mg/m2,a sap r o v o c a t i v ea g e n t
for GH secretion [24, 25]( Figure 1). The stimulated mean
peak GH value 60–90 minutes after clonidine was 9.1ng/mL
± 4.5 range (2.1–18.4). The mean IGF-1 value at that time
was 35.1 ± 17.7ng/dL (−2.5 SD for age- and gender-matched
normal range). Following the ﬁrst clonidine stimulation test,
patients were stratiﬁed by gender and age (4 to 18 months
and 19 to 37 months) and randomized to receive either GH
treatment (Genotropin, Pﬁzer, 1mg/m2/day) or observation
for 12 months (control, no GH treatment). Consequently,
half of the subjects were receiving GH during their second
clonidine study. After the initial 12 month study period, all
subjects received GH therapy for the duration of the study.
2.3. Study Protocol and Measurements. During the time of
clonidine provocative testing, patients were continuously
monitored by pulse oximetry and constantly observed by
a pediatric sedation study nurse for 2 hours following
clonidine administration. Heart rate, respiratory rate, blood
pressure, and oxygen saturation by pulse oximetry were
recorded at baseline and every 5 minutes on a sedation
monitoringrecord.Speciﬁctimeswererecordedfortheonset
of sleep and time to awakening. In addition, times were
recorded for the lowest oxygen saturation, blood pressure,
respiratory rate, and heart rate. A ﬁve-point pediatric
sedation score was recorded every ﬁve minutes to assess
the level of sedation: (1) agitated/clinging, (2) alert, awake,
not clinging, may whimper but not cry, (3) calm, lying
comfortably with eyes spontaneously open, (4) drowsy: lying
comfortably with eyes spontaneously closed but responds
to mild stimulation, and (5) asleep: eyes closed, does not
respond to mild stimulation [26]. The speciﬁc time when
patients achieved a sedation level of 4 or 5 was recorded.
A d v e r s ee v e n t sw e r ed e ﬁ n e da sa no x y g e ns a t u r a t i o n
of ≤94%, airway obstruction requiring intervention, apnea
and hypotension, or bradycardia requiring intervention.
Interventions performed to treat adverse events were at the
discretion of themonitoring nurse andrecorded atthattime.
2.4. Statistical Methods. Vital signs and body composition
parameters were summarized by standard descriptive statis-
tics in terms of means and standard deviations. BMI z-scores
were computed using the LMS method [27], based on the
reference values from the 2006 World Health OrganizationInternational Journal of Pediatric Endocrinology 3
Table 1: Patient population.
Study period
O v e r a l l # 1# 2# 3 # 4
Number of patients studied 17 17 16 15 12
Mean age (months) 30.4 ± 15.0 14.0 ± 6.8 26.1 ± 7.2 37.6 ± 6.9 50.2 ± 7.5
Male/Female 7/10 7/10 7/9 6/9 5/7
Mean clonidine dose (mg) 0.074 ± 0.027 0.058 ± 0.011 0.062 ± 0.021 0.072 ± 0.018 0.113 ± 0.02
Mean clonidine dose per kg (μg/kg) 5.3 ± 1.72 6.56 ± 1.08 5.09 ± 1.75 4.37 ± 1.18 4.97 ± 1.0
A total of 60 study periods were conducted over a 3-year period. Each study period was approximately 12 months apart. Seventeen patients were initially
enrolled in the study. Twelve patients completed all four study periods. Overall refers to the mean age and clonidine dose for all 60 study periods.
growth charts. Changes between baseline and postclonidine
administration assessments were evaluated using a repeated
measurement model with subject speciﬁc random eﬀects. In
order to account for correlations between repeated measure-
ments (visits 1–4) within the same subject, an autoregressive
correlation structure was assumed. Vital sign parameters
were log-transformed to perform the comparison between
the baseline and postclonidine assessment. Standard model
diagnostic tools were used to verify model assumptions.
Ap a i r e dt-test was used to evaluate changes between the
baseline and postclonidine assessmentat eachvisit. Box plots
were used to present the results graphically because they
illustrate important features such as outliers, spread, and
departure from symmetry. The comparison of BMI z-score
between subjects who achieved suﬃcient oxygen saturation
to those who did not achieve suﬃcient oxygen saturation
was performed using clustered t-test (clustering on subject).
All statistical tests were two sided, and P <.05 was used
to indicate statistical signiﬁcance. Statistical analyses were
performed using SAS version 9.1 software (SAS Institute,
Cary, NC).
3. Results
Seventeen patients were enrolled in the study, ten females
and seven males. Of the 17 patients 11 had paternal deletion,
ﬁve had uniparental maternal disomy, and one had DNA
methylation abnormalities consistent with an imprinting
center mutation. A total of sixty studies were conducted on
the 17 patients. All 17 patients were studied at least once, 16
patients twice, 15 patients three times, and 12 patients four
times. The overall mean age at the time of clonidine testing
was 30.4 ± 15.0 months (Table 1). The mean age for the ﬁrst
study was 14.0 ± 6.8 months, for the second study 26.1 ± 7.2
months, for the third study 37.6 ± 6.9 months, and for the
fourth study 50.2 ± 7.5 months.
All patients achieved a sedation score of 4 or 5 following
clonidine, consistent with a mild to moderate level of sleep.
The mean time from clonidine administration to the onset
of sleep was 34.3 ± 12.3 minutes. Overall, the mean decline
from baseline in heart rate was 19.3 ± 1 4 . 6b e a t s / m i n( P
<.001), respiratory rate 7.5 ± 6.1 breaths/min (P <.001),
systolic blood pressure 19.7 ± 14.6 mmHg (P <.001), and
diastolic blood pressure 12.8 ±16.6 (P =.006) (Figure 2).
The baseline mean oxygen saturation was 98.4 ± 1.3%
before clonidine. All patients had oxygen saturations ≥95%
at the beginning of each study period. Oxygen saturations
decreasedfrombaselineby2.2% ±2.0%(P<.001)following
clonidine. Absolute and percentage changes in individual
vital signs for each of the four study periods are tabulated
in Tables 2 and 3,r e s p e c t i v e l y .
Adverse Events. Nine oxygen desaturation events (oxygen
saturation ≤94%) occurred during the 60 study periods
(Table 4). The nine oxygen desaturations occurred in ﬁve
patients, four patients having an oxygen desaturation during
two separate study periods and one patient having one
oxygen desaturation. All patients experiencing an oxygen
desaturation event were female. The mean BMI z-score in
patients with an oxygen desaturation event was 1.74 ± 2.30
while the mean BMI z-score in all other subjects was 0.93 ±
1.58. However, there was no signiﬁcant association between
the occurrence of an oxygen desaturation event and BMI
z-score (P =.438). Seven of the nine oxygen desaturations
occurred during either the second or third study. Four
of the ﬁve patients had oxygen desaturations during the
second study period, two of whom were receiving GH. Three
episodes of oxygen desaturation were accompanied by mild
to moderate airway obstruction and sonorous respirations,
two of which were associated with an upper respiratory
tract infection. One patient was described as having irregular
respirations. All other oxygen desaturation episodes were
accompanied by shallow respirations. No child required
intervention above simple airway repositioning. Oxygen
saturation levels returned to baseline once the patient was
awake following the sedation and prior to discharge. No
interventions were required for blood pressure or heart rate.
4. Discussion
This study demonstrates that clonidine administration at
doses which are standard for provocative GH testing is
associated with respiratory depression deﬁned as an oxygen
saturation ≤94% and/or clinical signs of airway obstruction
(e.g., sonorous respirations) in children with PWS. Cloni-
dine consistently resulted in a reliable and moderate depth of
sedation that was accompanied by small reductions in heart
rate, respiratory rate, systolic blood pressure, and oxygen
saturation. Five patients, on nine separate occasions, devel-
oped moderate reductions in oxygen saturation following4 International Journal of Pediatric Endocrinology
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Figure 2: Changes in oxygen saturation, heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure following clonidine
treatment.Meandecreaseinoxygensaturationwas2.2 ±2.0(P <.001),heartrate19.3 ±14.6(P <.001),respiratoryrate7.5 ±6.1(P <.001),
systolic blood pressure 19.7 ± 14.6 (P <.001) and diastolic blood pressure 12.8 ± 16.6 (P =.006). Box plots for the distributions of oxygen
saturation, heart rate, respiratory rate, systolic blood pressure and diastolic blood pressure at baseline and post treatment. The horizontal
bold line shows the median while the box represents the 25th and 75th percentiles.International Journal of Pediatric Endocrinology 5
Table 2: Absolute changes of individual vital sign parameters following clonidine administration for each study period and overall.
Period Oxygen saturation (%) Heart rate Respiratory rate
Mean SD P-value Mean SD P –value Mean SD P -value
1 −2.3 1.6 <.001 −26.4 10.6 .000 −10.7 7.1 .000
2 −2.3 2 .001 −20 11.6 .000 −6.9 4.7 .000
3 −2.3 2.7 .005 −11.6 20.6 .047 −6.5 5.9 .002
4 −1.7 1.9 .010 −17.9 9.5 .000 −4.8 5 .007
Overall −2.2 2.0 <.001 −19.3 14.6 <.001 −7.5 6.1 <.001
Period Systolic blood pressure Diastolic blood pressure
Mean SD P -value Mean SD P -value
1 −19.8 13.1 .000 −7.5 15.7 .068
2 −19.5 12.5 .000 −14.9 23.7 .029
3 −14.8 11.7 .001 −14.2 8.5 .000
4 −25.1 20.8 .002 −16.4 13.9 .002
Overall −19.7 14.6 <.001 −12.8 16.6 .006
P-value was calculated using a paired t-test for study periods 1–4; a repeated measurement model with autoregressive correlation structure was used to
compute P-value for overall comparison.
Table 3: Percentage changes of individual vital sign parameters following clonidine administration for each study period and overall.
Period Oxygen saturation (%) Heart rate Respiratory rate
Mean SD P-value Mean SD P –value Mean SD P -value
1 −2.3 1.7 <.001 −20.8 7.8 <.001 −32.3 17.1 <.001
2 −2.3 2.1 .001 −16.7 9.6 .000 −26.6 16.4 <.001
3 −2.3 2.7 .005 −8.9 23.8 .170 −25.6 20.8 .001
4 −1.7 1.9 .010 −16.6 7.4 .000 −18.4 17.3 .004
Overall −2.1 2.1 <.001 −15.9 14.3 <.001 −26.3 18.1 <.001
Period Systolic blood pressure Diastolic blood pressure
Mean SD P -value Mean SD P -value
1 −19.1 10.8 .000 −6.3 40.6 .532
2 −18.8 11.1 .000 −13.7 48.8 .296
3 −14.6 11 .000 −22 13.4 .000
4 −20.2 16 .001 −20.1 22.8 .011
Overall −18.2 12.0 <.001 −14.7 35.6 .005
P-value was calculated using a paired t-test for study periods 1–4; a repeated measurement model with autoregressive correlation structure was used to
compute P-value for overall comparison.
clonidine administration. To our knowledge this is the ﬁrst
reporttodemonstraterespiratorydepressioninpatientswith
PWS following a standard dose of clonidine used to assess
GHsecretionresponse.Collapsibilityoftheupperairwaydue
to a depressed level of consciousness and loss of pharyngeal
muscle tone is one of the most serious complications
following sedative-anesthetic drug administration [28–30].
In this regard, clonidine is a sedative used in anesthetic
practice and has potential to cause problems with upper
airwaytone.Itislikelythatrespiratorycontroldysfunctionin
PWS patients, the respiratory depressant eﬀects of clonidine,
and the relatively high doses used to assess GH secretion
create a heightened risk for respiratory depression in these
children.
Numerous studies have demonstrated abnormal sleep
patterns in patients with PWS that include hypoventilation,
oxygen desaturation and sleep apnea [11–13, 31–36]. In
addition to ventilation control abnormalities, children with
PWS have additional risk factors that predispose them to
abnormal pulmonary function and respiratory responsive-
ness. Hypotonia, obesity, and reduced muscle mass con-
tributetooverallrespiratorypumpweaknessandarestrictive
lung pattern in patients with PWS [37]. While none of our
PWSpatientswereobese,abnormalitiesinbodycomposition
are already present during infancy [22], including reduced
muscle mass, which may have contributed to the overall
reduction in airway tone and ventilatory response following
clonidine.
Recent reports of sudden death in children with PWS
receiving GH supplementation have focused attention on
the underlying respiratory disturbances in PWS. Our study
was not designed to assess the eﬀects of GH treatment
on respiratory function on patients with PWS. Studies
have demonstrated that pulmonary dysfunction directly
contributes to mortality in the majority of PWS whether or
not they are receiving GH [7–9]. Indeed, in a multicenter6 International Journal of Pediatric Endocrinology
Table 4: PWS patients experiencing an oxygen desaturation.
Patient (sex) Age
mos
Visit
#
Receiving
Growth
Hormone
Clonidine
dose, mg
(μg/kg)
Sleep
onset
(min)
Lowest
SpO2
(%)
BMI BMI
Z-score Comments
1( F )
• 15q11-13 deletion
• No history of sleep apnea
9 1 No 0.06 (7.1) 30 89% 17.3 0.37 Current upper respiratory
infection
20 2 Yes 0.075 (6.1) 20 93% 16.3 0.51
Current upper respiratory
infection
Sonorous respirations
2( F )
• 15q11-13 deletion
• No history of sleep apnea
• History of snoring
17 2 Yes 0.05 (4.9) 30 91% 16.7 0.62 —
29 3 Yes 0.05 (4.0) 30 90% NR NR —
3( F )
• 15q11-13 deletion
• History of sleep apnea
• History of snoring
27 2 No 0.025 (2.0)
(dose reduced) 45 92% 15.8 0.15
Current upper respiratory
infection
No snoring
39 3 Yes 0.05 (2.6)
(dose reduced) 37 93% 20.7 3.18
Current upper respiratory
infection
Mild airway obstruction
4( F )
• 15q11-13 deletion
• History of respiratory
pauses during sleep
28 2 No 0.07 (5.9) 33 92% 16.3 0.53 Irregular breathing with
pauses
40 3 Yes 0.075 (6.4) 53 94% 14.2 −0.90 —
5( F )
• 15q11-13 deletion
• Occasional snoring
48 4 Yes 0.125 (5.9) 31 94% 16.1 0.58 Sonorous respirations
Characteristics of the 5 patients experiencing an oxygen desaturation on 9 separate occasions.
BMI Z-scores were computed with the LMS method using WHO reference values for gender and age.
NR—Not recorded.
randomized controlled study no signiﬁcant changes in sleep-
related apneas or hypopneas were seen in young PWS
patients receiving GH treatment [38]. Tauber et al. found
that 61% of sudden deaths in children with PWS were
directly attributed to a respiratory problem [9]. An upper
respiratory infection was present in four of the nine episodes
of oxygen desaturation in our study.
An intrinsic abnormality of respiratory drive in children
withPWScouldbe exacerbatedby therespiratory depressant
eﬀects of clonidine. Clonidine has few clinically signiﬁcant
respiratory depressant eﬀects when used at doses of 3 to
4μg/kg [14, 16, 39–46]. In otherwise healthy adults declines
inoxygensaturationwere ≤1%followingoralclonidine[15].
Similarly, no oxygen saturations <95% were observed in
children receiving 4μg/kg of oral clonidine as a preanesthetic
medication [16]. In fact, clonidine is considered so safe in
this setting that few studies even discuss monitoring oxygen
saturations following administration. Indeed only one study,
adult patients without PWS, has demonstrated decreases
in oxygen saturation that were accompanied by partial
airway obstruction following clonidine as a preanesthetic
medication [47]. Of the nine oxygen desaturations in the
children with PWS in our study, four were associated with
partial airway obstruction.
The standard dose of clonidine to assess GH respon-
siveness is 0.15mg/m2 [24, 25]. Interestingly, this dosing,
based on surface area, resulted in a mean clonidine dose of
6.56μg/kg during the ﬁrst study and 5.3μg/kg for all studies
overall. Consequently clonidine doses were 1.5 to 2 times
greaterthantypicaldosesusedasapreanestheticmedication.
To our knowledge use of pulse oximetry to assess respiratory
function following clonidine for GH stimulation has not
been studied. Yet, doses of clonidine for GH stimulation
often exceed amounts identiﬁed in unintentional ingestions
as potentially toxic [21]. In a recent study examining
clonidine ingestions in children, Spiller et al., recommended
direct medical evaluation of all children 4 years of age and
younger for clonidine ingestions of 0.1mg and/or 5μg/kg or
greater. Interestingly, of the 60 clonidine administrations in
our study the average dose of clonidine exceeded 5μg/kg and
42(70%)dosesofclonidinewereequaltoorexceeded0.1mg
or 5μg/kg. In patients experiencing low oxygen saturation
ﬁve of the nine (55%) administrations exceeded 5μg/kg.
While our setting and patient population is diﬀerent than
that described by Spiller et al., the recognition that doses
of this amount have potential for serious adverse events in
childrenisconsistentwithourﬁndingsinpatientswithPWS.
A limitation to our study was that it did not have the
rigor of a blinded randomized controlled investigation. The
lack of an alternative-treatment control group prevented us
from being able to discern whether clonidine administration
per se caused these respiratory abnormalities or was merely
associated with them. We chose this design in order to
assess a standard assessment tool. A randomized, placebo,
controlled study will be necessary to clarify the respiratory
eﬀects of clonidine.International Journal of Pediatric Endocrinology 7
Secondly, detailed baseline sleep study information was
not available for all patients. Since PWS patients often
have sleep disordered breathing, the oxygen desaturation
events in our 5 patients may simply represent what typically
occurs in these patients during sleep. In addition, four
oxygen desaturation episodes were in the presence of an
upper respiratory tract infection. The presence of an upper
respiratory infection may have exacerbated the respiratory
dysfunction in this patient population following clonidine
administration. Whether clonidine simply simulates what
happens during normal sleep in PWS patients or accentuates
an underlying respiratory control problem is unclear.
We used a deﬁnition of an oxygen desaturation of less
than or equal to 94% as an adverse event. We chose to
have a low threshold for reporting an oxygen desaturation in
an eﬀort to increase the sensitivity for detecting respiratory
depression in our patient population. Our deﬁnition of an
oxygen desaturation is similar to that used in other studies
evaluating the safety of clonidine [47].
In conclusion, while the majority of patients with
PWS developed only minimal respiratory changes following
clonidine administration, a subset of patients experienced
reductions in oxygen saturation that were accompanied by
partial airway obstruction or shallow respirations. Further,
clonidine doses used for GH stimulation in children are
substantially greater than doses routinely used for sedation
andinourpatientpopulationresultedinamoderatedepthof
sedation. The American Academy of Pediatrics recommends
continuous monitoring of oxygen saturation and heart rate
for all patients receiving moderate sedation [48]. In our
study all patients achieved a sedation level of 4 (drowsy,
responds to mild stimulation) or 5 (asleep, does not respond
to mild stimulation), following clonidine administration.
This degree of sedation is consistent with the deﬁnition
of moderate to deep sedation. Because of the large doses
of clonidine used for GH stimulation and the intrinsic
respiratory dysfunction in children with PWS we would
recommend that all PWS patients receiving clonidine for
GH stimulation receive continuous monitoring by pulse
oximetry and be cared for by personnel proﬁcient in
the monitoring and management of the sedated pediatric
patient. Further prospective studies are required to assess the
risk of clonidine use in patients with PWS.
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